BRENDA COLATRELLA, an executive of the multinational pharmaceutical giant Merck & Co., remembers being stunned at a meeting back in 1996 by a proposal made by a colleague at the World Health Organization (WHO). Since 1987, Merck and the WHO had been partners in an innovative program to eliminate onchocerciasis, a leading cause of blindness in the developing world. Merck’s donations of its breakthrough drug Mectizan, with the WHO’s technical support, had already saved millions of Africa’s poor...
Want more? Sorry, the full text of this article is only available to subscribers. Subscribe now.
Already a subscriber? Please log in by entering your email address and password into the red login box at the top-right corner of this page.
Need to register for your premium online access, which is included with your paid subscription? Register here.